# LTBR

## Overview
The LTBR gene encodes the lymphotoxin beta receptor, a type I transmembrane protein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. This receptor is characterized by its extracellular domain, which contains cysteine-rich motifs essential for ligand binding and receptor activation, and a cytoplasmic tail that is pivotal for intracellular signaling. The lymphotoxin beta receptor plays a crucial role in the development and maintenance of lymphoid tissues, influencing processes such as the formation of lymph nodes and Peyer's patches, and the organization of the thymic medulla. It is involved in various signaling pathways, including those mediated by NF-κB, and interacts with several proteins, such as TRAF2 and TRAF3, to regulate immune responses. Alterations in LTBR expression have been linked to inflammatory and autoimmune diseases, as well as certain leukemias, highlighting its significance in both physiological and pathological contexts (Riffelmacher2021Metabolic; Fütterer1998The; Borelli2021Lymphotoxin:).

## Structure
The lymphotoxin beta receptor (LTBR) is a type I transmembrane protein that is part of the tumor necrosis factor receptor (TNFR) superfamily. Its molecular structure includes an extracellular domain characterized by cysteine-rich motifs, which are crucial for its function in ligand binding and receptor activation. The protein also features a single transmembrane helix that anchors it within the cell membrane, and a cytoplasmic tail that plays a significant role in intracellular signaling pathways.

LTBR is subject to post-translational modifications, such as glycosylation, which can influence its stability, localization, and interaction with other molecules. These modifications are essential for the proper functioning of the receptor in immune response regulation.

The gene encoding LTBR may produce splice variant isoforms, which can lead to differences in the receptor's function. These isoforms may alter the receptor's ability to interact with ligands or other signaling molecules, thereby affecting its role in immune system processes. The presence of these isoforms highlights the complexity and adaptability of LTBR in various physiological contexts.

## Function
The lymphotoxin beta receptor (LTBR) is a critical component in the development and function of lymphoid tissues. It plays a pivotal role in the organogenesis of peripheral lymphoid tissues, including the formation of Peyer's patches, lymph nodes, and the architecture of the spleen. LTBR is essential for the proper formation of germinal centers and follicular dendritic cell networks, which are crucial for antibody affinity maturation (Fütterer1998The). 

LTBR signaling is involved in the regulation of chemokine production, influencing the recruitment and composition of antigen-presenting cells in the thymus. This signaling pathway is vital for the organization of the thymic medulla, affecting the development and spatial arrangement of medullary thymic epithelial cells (Borelli2021Lymphotoxin:). 

In adulthood, LTBR maintains the structure and function of lymphoid organs, such as lymph nodes and Peyer's patches, by influencing the migration of naïve lymphocytes and the production of homeostatic chemokines like CXCL13, CCL19, and CCL21 (Shou2021Redefining). 

LTBR is also crucial for the homeostasis of dendritic cells in lymphoid tissues, promoting their maintenance and maturation through signaling pathways that involve NF-κB (Kabashima2005Intrinsic).

## Clinical Significance
Alterations in the expression of the lymphotoxin beta receptor (LTBR) have been implicated in various inflammatory and autoimmune diseases. In the context of inflammatory bowel disease (IBD), particularly colitis, LTBR expression in neutrophils is crucial for preventing severe disease manifestations. The absence of LTBR in neutrophils leads to increased metabolic activity and reactive oxygen species (ROS) production, exacerbating colitis symptoms. This suggests that LTBR plays a protective role by regulating neutrophil metabolism and preventing excessive inflammation (Riffelmacher2021Metabolic).

In Sjögren's syndrome, an autoimmune disease affecting secretory glands, the LTBR pathway is associated with the development of tertiary lymphoid tissues at sites of chronic inflammation. Blocking LTBR in a mouse model of Sjögren's syndrome reduces B-cell accumulation and improves glandular function, indicating its potential therapeutic target in this condition (Fava2011Lymphotoxinbeta).

LTBR signaling is also involved in the progression of certain leukemias. In chronic myeloid leukemia (CML), LTBR promotes the proliferation and maintenance of leukemia stem cells, contributing to disease progression. Alterations in LTBR expression or function could be associated with hematopoietic disorders and leukemia, particularly under genotoxic stress (Höpner2021LIGHTLTβR).

## Interactions
The lymphotoxin beta receptor (LTBR) interacts with several proteins, primarily through its cytoplasmic domain, which is crucial for initiating signaling pathways. LTBR forms a complex with tumor necrosis factor receptor-associated factor 3 (TRAF3) in a ligand-dependent manner, specifically after treatment with recombinant soluble LTα1β2 or an agonistic LTβR monoclonal antibody. This interaction is rapid, occurring within a minute of ligand binding, and is an early event in LTβR signaling (VanArsdale1997Lymphotoxinβ). TRAF3 is recruited to the LTβR complex, playing a critical role in cell death signaling, while TRAF2 and TRAF5 are involved in NF-κB activation (VanArsdale1997Lymphotoxinβ; Norris2024The).

TRAF2 is essential for LIGHT-induced NF-κB and JNK activation through LTβR, forming a signaling complex upon LIGHT treatment. This interaction is sustained for several hours, highlighting TRAF2's role in maintaining the signaling pathway (Kim2005TRAF2). TRAF3, on the other hand, acts as a negative regulator of LTβR signaling, modulating the balance between canonical and non-canonical NF-κB pathways by affecting TRAF2 recruitment (Bista2010TRAF3). These interactions underscore the complexity of LTβR signaling, involving multiple TRAF proteins that contribute to diverse cellular outcomes.


## References


[1. (Shou2021Redefining) Yajun Shou, Ekaterina Koroleva, Cody M. Spencer, Sergey A. Shein, Anna A. Korchagina, Kizil A. Yusoof, Raksha Parthasarathy, Elizabeth A. Leadbetter, Armen N. Akopian, Amanda R. Muñoz, and Alexei V. Tumanov. Redefining the role of lymphotoxin beta receptor in the maintenance of lymphoid organs and immune cell homeostasis in adulthood. Frontiers in Immunology, July 2021. URL: http://dx.doi.org/10.3389/fimmu.2021.712632, doi:10.3389/fimmu.2021.712632. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2021.712632)

[2. (Höpner2021LIGHTLTβR) S. S. Höpner, Ana Raykova, R. Radpour, M. A. Amrein, D. Koller, G. M. Baerlocher, C. Riether, and A. F. Ochsenbein. Light/ltβr signaling regulates self-renewal and differentiation of hematopoietic and leukemia stem cells. Nature Communications, February 2021. URL: http://dx.doi.org/10.1038/s41467-021-21317-x, doi:10.1038/s41467-021-21317-x. This article has 10 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-021-21317-x)

[3. (VanArsdale1997Lymphotoxinβ) Todd L. VanArsdale, Sammee L. VanArsdale, Walker R. Force, Barbara N. Walter, George Mosialos, Elliott Kieff, John C. Reed, and Carl F. Ware. Lymphotoxin-β receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor κb. Proceedings of the National Academy of Sciences, 94(6):2460–2465, March 1997. URL: http://dx.doi.org/10.1073/pnas.94.6.2460, doi:10.1073/pnas.94.6.2460. This article has 138 citations.](https://doi.org/10.1073/pnas.94.6.2460)

[4. (Bista2010TRAF3) Pradeep Bista, Weike Zeng, Sarah Ryan, Veronique Bailly, Jeffrey L. Browning, and Matvey E. Lukashev. Traf3 controls activation of the canonical and alternative nfκb by the lymphotoxin beta receptor. Journal of Biological Chemistry, 285(17):12971–12978, April 2010. URL: http://dx.doi.org/10.1074/jbc.m109.076091, doi:10.1074/jbc.m109.076091. This article has 95 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m109.076091)

[5. (Kabashima2005Intrinsic) Kenji Kabashima, Theresa A. Banks, K. Mark Ansel, Theresa T. Lu, Carl F. Ware, and Jason G. Cyster. Intrinsic lymphotoxin-β receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity, 22(4):439–450, April 2005. URL: http://dx.doi.org/10.1016/J.IMMUNI.2005.02.007, doi:10.1016/j.immuni.2005.02.007. This article has 374 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/J.IMMUNI.2005.02.007)

[6. (Riffelmacher2021Metabolic) Thomas Riffelmacher, Daniel A. Giles, Sonja Zahner, Martina Dicker, Alexander Y. Andreyev, Sara McArdle, Tamara Perez-Jeldres, Esmé van der Gracht, Mallory Paynich Murray, Nadine Hartmann, Alexei V. Tumanov, and Mitchell Kronenberg. Metabolic activation and colitis pathogenesis is prevented by lymphotoxin β receptor expression in neutrophils. Mucosal Immunology, 14(3):679–690, May 2021. URL: http://dx.doi.org/10.1038/s41385-021-00378-7, doi:10.1038/s41385-021-00378-7. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41385-021-00378-7)

[7. (Fava2011Lymphotoxinbeta) Roy A Fava, Susan M Kennedy, Sheryl G Wood, Anne I Bolstad, Jadwiga Bienkowska, Adrian Papandile, John A Kelly, Clio P Mavragani, Margaret Gatumu, Kathrine Skarstein, and Jeffrey L Browning. Lymphotoxin-beta receptor blockade reduces cxcl13 in lacrimal glands and improves corneal integrity in the nod model of sjögren’s syndrome. Arthritis Research &amp; Therapy, November 2011. URL: http://dx.doi.org/10.1186/ar3507, doi:10.1186/ar3507. This article has 69 citations.](https://doi.org/10.1186/ar3507)

[8. (Kim2005TRAF2) You-Sun Kim, Sergei A. Nedospasov, and Zheng-gang Liu. Traf2 plays a key, nonredundant role in light-lymphotoxin β receptor signaling. Molecular and Cellular Biology, 25(6):2130–2137, March 2005. URL: http://dx.doi.org/10.1128/mcb.25.6.2130-2137.2005, doi:10.1128/mcb.25.6.2130-2137.2005. This article has 45 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.25.6.2130-2137.2005)

[9. (Borelli2021Lymphotoxin:) Alexia Borelli and Magali Irla. Lymphotoxin: from the physiology to the regeneration of the thymic function. Cell Death &amp; Differentiation, 28(8):2305–2314, July 2021. URL: http://dx.doi.org/10.1038/s41418-021-00834-8, doi:10.1038/s41418-021-00834-8. This article has 27 citations.](https://doi.org/10.1038/s41418-021-00834-8)

10. (Norris2024The) The LTβR Signaling Pathway. This article has 24 citations.

[11. (Fütterer1998The) Agnes Fütterer, Karin Mink, Arne Luz, Marie H. Kosco-Vilbois, and Klaus Pfeffer. The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity, 9(1):59–70, July 1998. URL: http://dx.doi.org/10.1016/s1074-7613(00)80588-9, doi:10.1016/s1074-7613(00)80588-9. This article has 606 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s1074-7613(00)80588-9)